Correction | Published:

Corrections

Nature volume 441, page 141 (11 May 2006) | Download Citation

Subjects

The article ‘Can super-antibody drugs be tamed?’ (Nature 440, 855–856; 2006) contained two errors. Steve Anderton researches autoimmune disease, not the use of antibodies to overcome cancer. And he did not state that the CD25 receptor may be a safer target for antibody therapies than CD28; instead, he suggested that CD25 may be of some use as a marker for regulatory T cells, and that other costimulatory molecules, such as CD154, may represent safer targets for immunomodulatory antibodies. Nature apologizes for any confusion.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/441141a

Authors

    Comments

    By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.